Radiopharm Theranostics Limited American Depositary Shares (RADX) - Total Assets
Based on the latest financial reports, Radiopharm Theranostics Limited American Depositary Shares (RADX) holds total assets worth $91.08 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Radiopharm Theranostics Limited American (RADX) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Radiopharm Theranostics Limited American Depositary Shares - Total Assets Trend (2022–2025)
This chart illustrates how Radiopharm Theranostics Limited American Depositary Shares's total assets have evolved over time, based on quarterly financial data. See net assets of Radiopharm Theranostics Limited American for net asset value and shareholders' equity analysis.
Radiopharm Theranostics Limited American Depositary Shares - Asset Composition Analysis
Current Asset Composition (June 2025)
Radiopharm Theranostics Limited American Depositary Shares's total assets of $91.08 Million consist of 46.1% current assets and 53.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 33.7% |
| Accounts Receivable | $10.40 Million | 12.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $46.57 Million | 53.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Radiopharm Theranostics Limited American Depositary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Radiopharm Theranostics Limited American.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Radiopharm Theranostics Limited American Depositary Shares's current assets represent 46.1% of total assets in 2025, an increase from 32.7% in 2022.
- Cash Position: Cash and equivalents constituted 33.7% of total assets in 2025, up from 32.4% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 53.0% of total assets, a decrease from 67.0% in 2022.
- Asset Diversification: The largest asset category is intangible assets at 53.9% of total assets.
Radiopharm Theranostics Limited American Depositary Shares Competitors by Total Assets
Key competitors of Radiopharm Theranostics Limited American Depositary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Radiopharm Theranostics Limited American Depositary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.01 | 3.37 | 3.46 |
| Quick Ratio | 3.01 | 3.37 | 3.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $30.72 Million | $31.21 Million | $19.39 Million |
Radiopharm Theranostics Limited American Depositary Shares - Advanced Valuation Insights
This section examines the relationship between Radiopharm Theranostics Limited American Depositary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.10 |
| Latest Market Cap to Assets Ratio | 0.27 |
| Asset Growth Rate (YoY) | 20.1% |
| Total Assets | $86.48 Million |
| Market Capitalization | $23.02 Million USD |
Valuation Analysis
Below Book Valuation: The market values Radiopharm Theranostics Limited American Depositary Shares's assets below their book value (0.27x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Radiopharm Theranostics Limited American Depositary Shares's assets grew by 20.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Radiopharm Theranostics Limited American Depositary Shares (2022–2025)
The table below shows the annual total assets of Radiopharm Theranostics Limited American Depositary Shares from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $86.48 Million | +20.05% |
| 2024-06-30 | $72.04 Million | -3.89% |
| 2023-06-30 | $74.95 Million | -10.11% |
| 2022-06-30 | $83.38 Million | -- |
About Radiopharm Theranostics Limited American Depositary Shares
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more